A newly approved daily eye drop priced at about 3 dollars a dose could allow millions of people in midlife to put aside their reading glasses for much of the day.
The prescription product, named VIZZ, has just secured clearance in the United States as the first treatment developed specifically for presbyopia, the age-related loss of near vision that affects the vast majority of adults over 45.
Instead of reshaping the eye’s lens, the drops act on the pupil. By slightly constricting it, they create a “pinhole effect” similar to squinting, which cuts down on stray light and channels the most focused light rays toward the retina. This increases depth of focus, helping users see nearby objects such as mobile screens, restaurant menus and books more clearly again.
In late-stage clinical trials, about 71 percent of participants reported a meaningful improvement in near vision within half an hour of applying the drops. For many, the benefit persisted for up to 10 hours, potentially covering a full workday with a single administration. That could mean patients are able to read, text and do close-up tasks without repeatedly reaching for reading glasses.
Presbyopia stems from the gradual stiffening of the eye’s natural lens, which typically begins in the 40s and reduces its ability to shift focus from far to near objects. Until now, most people have managed the condition with reading glasses, bifocals or specialized contact lenses, often juggling multiple pairs or constantly putting glasses on and off throughout the day. VIZZ is being presented as a simpler, non-invasive alternative.
The drop’s active ingredient, aceclidine, is not new to eye care but has been reformulated to act mainly on the iris — the colored ring that controls pupil size — rather than the lens itself. This targeted mechanism is designed to boost near vision without degrading distance vision, a trade-off seen with some other presbyopia treatments. Across the trials, 40 percent of users who initially responded maintained the same level of near-vision gain 10 hours after instillation.
Regulatory approval was based on several phase III studies involving hundreds of volunteers. In one key programme, 466 people self-administered the drops daily for six weeks, while additional research followed participants longer term to assess safety. No serious adverse events emerged in the data submitted. The most frequently reported side effects were mild and short-lived, including slight eye irritation, temporary redness and a brief dimming of vision immediately after use.
Early users have described striking benefits. One participant said they were able to read their smartphone without glasses for the first time in five years within 20 minutes of applying the drops. Clinicians involved in the research say the product could reshape routine care for presbyopia, offering eye doctors a new tool alongside traditional optical aids. “This will be a welcome solution,” one trial investigator said, predicting rapid uptake among optometrists and ophthalmologists.
Specialists still warn that VIZZ will not completely replace reading glasses in every scenario. People may continue to need spectacles in very low light or for extremely fine print, where any presbyopia treatment is challenged. Nonetheless, with more than 100 million adults in the US alone affected by age-related near-vision loss, the potential reach is enormous. As populations age globally, demand for simple, non-surgical options like VIZZ is expected to grow. For those frustrated by constantly misplacing their glasses, the prospect of restoring comfortable near vision with a once-daily eye drop could prove transformative.
📢 For the latest International & UAE news and analysis join ProPakistani's WhatsApp Group now!
Follow ProPakistani on Google News & scroll through your favourite content faster!
Shares
